AGTC conducts human clinical trials of adeno-associated virus-based gene therapies for the treatment of rare inherited retinal diseases.

Washer will provide a corporate update and talk about AGTC's plans to move late-stage X-linked retinitis pigmentosa and achromatopsia clinical programs forward, the company said.

AGTC expands gene therapy manufacturing capabilities
Applied Genetic Technologies (AGTC) has initiated plans to lease a build-to-suit 21,000-sq-ft current good manufacturing practice manufacturing and quality...

AGTC touts positive early clinical results for gene therapy
Applied Genetic Technologies (AGTC) has reported positive data from its ongoing phase I/II clinical trial evaluating its adeno-associated virus (AAV)-based...

Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...